BioMed Research International

BioMed Research International / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 617868 |

Yongfu Ma, Hui Xia, Yang Liu, Min Li, "Silencing miR-21 Sensitizes Non-Small Cell Lung Cancer A549 Cells to Ionizing Radiation through Inhibition of PI3K/Akt", BioMed Research International, vol. 2014, Article ID 617868, 6 pages, 2014.

Silencing miR-21 Sensitizes Non-Small Cell Lung Cancer A549 Cells to Ionizing Radiation through Inhibition of PI3K/Akt

Academic Editor: Hushan Yang
Received21 Dec 2013
Revised28 Feb 2014
Accepted02 Mar 2014
Published07 Apr 2014


We investigated the role of microRNA-21 (miR-21) in radiotherapy resistance of non-small cell lung cancers (NSCLC) and the underlying molecular mechanism. A549 cells were transfected with anti-miR-21 or the negative control oligonucleotides and real-time PCR was applied to detect miR-21 expression level. After ionizing radiation (IR), the survival fractions, proliferation, apoptosis, and expression of phosphorylated-Akt of A549 cells were determined by clonogenic survival analysis, MTT assay, flow cytometry, and Western blotting. Downregulation of miR-21 in radioresistant NSCLC A549 cells inhibited the colony-forming ability and proliferation of A549 cells after IR. Moreover, silencing miR-21 enhanced apoptosis of A549 cells induced by IR accompanied by decreased phosphorylated-Akt protein level. However, PI3K activator IGF-1 reversed suppression of phosphorylated-Akt protein level and promotion of apoptosis of A549 cells after IR caused by miR-21 knockdown. Silencing miR-21 in radioresistant NSCLC A549 cells sensitized them to IR by inhibiting cell proliferation and enhancing cell apoptosis through inhibition of PI3K/Akt signaling pathway. This might help in sensitization of NSCLC to radiotherapy.

1. Introduction

Lung cancer is the leading cause of cancer-related deaths worldwide [1], whereas non-small cell lung cancer (NSCLC) represents the most frequent type of lung cancer [2]. NSCLC accounts for approximately 80% of all lung cancer cases and has a 5-year overall survival rate of less than 15% [3, 4]. Approximately 40% of patients diagnosed with NSCLC have unresectable stage III disease or medically inoperable disease [5].

Radiation therapy has been regarded as the main treatment strategy for NSCLC for a long time. However, radioresistance is the key issue limiting the effects of radiotherapy [2, 6]. It is possibly due to tumor heterogeneity in terms of cell of origin, pathology, etiology, and molecular/genetic pathogenesis [7]. NSCLC cells are often resistant to radiotherapy [8], which in turn induces the local recurrence of NSCLC [9, 10]. Therefore, the development of novel approaches for the treatment of NSCLC, including targeted gene treatment as a radiosensitizer to treat this lethal disease, is urgently needed to enhance the survival rate in patients.

microRNAs (miRNAs) [11] are a class of short noncoding RNAs that function as a regulation for gene expression via targeting mRNA for degradation or inhibition of translation [12]. miRNAs are new factors implicated in regulating the expression of genes involved in tumorigenic processes, such as inflammation, cell cycle regulation, stress response, differentiation, apoptosis, and invasion, and over the past decade they have been found to have key roles in cancers [1315], including lung cancer [16]. Moreover, recent studies have suggested a link between expression of some miRNAs and radiotherapy, particularly in lung cancer [1719].

microRNA-21 (miR-21) is a miRNA which has been reported to be overexpressed in many human malignancies including NSCLC [2022]. Interestingly, miR-21 was found to be upregulated in radiotherapy resistant NSCLC cells relative to radiosensitive counterparts [18]. In addition, Wang et al. also reported that, comparing with radiotherapy resistant NSCLC patients, miR-21 was greatly downregulated in radiotherapy sensitive group [23]. Considering miR-21 as a putative regulator of NSCLC radiotherapy resistance, we explore the role of miR-21 in radiotherapy resistance of NSCLC A549 cells and the potential molecular mechanism in the present study.

2. Materials and Methods

2.1. Cell Culture

The NSCLC cell line A549 was cultured in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. Cell cultures were incubated in a humidified atmosphere of 5% CO2 at 37°C.

2.2. Transfection

Anti-miR-21 (5′-UCAACAUCA-GUCUGAUAAGCUA-3′) and the negative control oligonucleotides (NC, 5′-CAGUACUUUUG-UGUAGUACAA-3′) were obtained from Ambion Inc. (Austin, TX, USA). The transfection was performed using LipofectamineTM 2000 (Invitrogen, USA) according to the instructions provided by the manufacturer. The transfected cells were resuspended and cultured in regular culture medium for 48 h before analysis.

2.3. Detection of miR-21 by TaqMan Real-Time PCR

PCR-based detection of miR-21 was performed by the TaqMan miRNA assays (ABI, Forest City, CA) as described previously [24, 25]. The real-time PCR results, recorded as threshold cycle numbers (Ct), were normalized against an internal control (U6 RNA) and then expressed as fold changes [25].

2.4. Ionizing Radiation

48 h after anti-miR-21 or anti-miR-NC transfection, subconfluent cell monolayers were treated with γ-ray ionizing radiation (IR) from a 60Co source (PLA General Hospital, Beijing, China) at a rate of 2.4 Gy/min.

2.5. Clonogenic Survival Analysis

After exposure to various doses of IR, cells were trypsinized, washed, and replated at 200 cells per 10-cm dishes. Cells were grown for 14 days, fixed with ethanol, and stained with Giemsa to detect colonies. The number of colonies containing at least 50 cells was determined, and surviving fractions were calculated.

2.6. MTT Assay

Twenty-four hours before IR, 200 μL cells were seeded to 96-well microtiter plate at 5 × 104 cells/mL. Three days after IR, 10 μL MTT reagent was added to each well, followed by incubation for 4 h at 37°C. The supernatants were aspirated and the reaction was terminated by adding 100 μL DMSO. The contents of the plates were mixed for 10 min and the absorbance was read at 490 nm. All experiments were performed three times and the average results were calculated.

2.7. Flow Cytometry

Attached cells were harvested at 48 h after IR for apoptosis detection using the annexin V-FITC apoptosis detection kit (Sigma, Louis, MO). Briefly, the cells were washed twice with DPBS and then were resuspended in 1× binding buffer at a concentration of 1 × 106 cells/mL. 5 μL of annexin V-FITC conjugate and 10 μL of propidium iodide solution were added to 500 μL of each cell suspension in a plastic 12 mm × 75 mm test tube, followed by incubation at room temperature for 15 min and protection from light. The fluorescence of the cells was determined immediately with a flow cytometer. 10 ng/mL of PI3K activator IGF-1 (Prospec-Tany, Rehovot, Israel) was used in the apoptosis assay.

2.8. Western Blot Analysis

Cells were lysed in lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1 mM EDTA, 1 mM EGTA, 2 mM sodium orthovanadate, 2 mM NaF, and Complete TM Protease Inhibitor Mix [Roche Applied Science, Mannheim, Germany]) for 20 min on ice and cleared by centrifugation at 12,000 rpm and 4°C. Proteins were resolved on a 10% SDS PAGE gel, transferred onto nitrocellulose membranes, and blocked with 5% nonfat dry milk in TBST (10 mM Tris-HCl pH 7.5, 100 mM NaCl, and 0.05% Tween 20), followed by incubation with a primary antibody [total and anti-phosphorylated-Akt (Ser473) antibody (Cell Signaling Biotechnology, Beverly, MA, USA)]. Blots were washed and incubated with horseradish peroxidase-conjugated secondary antibody. Antibody complexes were visualized using an enhanced chemiluminescence-Western blotting detection system (Thermo Fisher Scientific, Inc., Rockford, IL, USA).

2.9. Statistical Analysis

Statistical analysis was performed using SPSS 13.0. The results from three independent experiments were presented as the means ± standard deviation. Statistical analyses were done by Student’s -test. value < 0.05 was considered statistically significant.

3. Results

3.1. miR-21 Expression Was Knocked down in A549 Cells by Anti-miR-21 Transfection

To confirm knockdown efficiency of anti-miR-21 transfection, the relative of miR-21 expression level was detected by real-time quantitative RT-PCR. Compared with anti-miR-NC-transfected A549 cells, the level of miR-21 expression in anti-miR-21-transfected cells was significantly decreased by about 64% (Figure 1).

3.2. Downregulation of miR-21 Inhibited Survival Capacity of A549 Cells after IR

To assess whether miR-21 downregulation could sensitize NSCLC A549 cells to IR, the A549 cells transfected with either anti-miR-NC or anti-miR-21 were irradiated and their response was analysed. In clonogenic survival analysis, we observed the expected decreased survival capacity of A549 cells transfected with anti-miR-21 14 days after IR (Figure 2). Forty-eight hours after transfection, A549 cells were treated with various doses of IR (0, 2, 4, 6, or 8 Gy) and the survival fractions upon IR were detected. As shown in Figure 2, after IR at 4, 6, or 8 Gy, the survival fraction of A549 cells in anti-miR-21-transfected group (, , and , resp.) was significantly lower than that in anti-miR-NC-transfected group (, , and , resp.), indicating that downregulation of miR-21 could significantly enhance the sensitivity of A549 cells to IR.

3.3. Downregulation of miR-21 Suppressed Proliferation of A549 Cells after IR

To confirm the increased IR sensitivity of A549 cells, the effect of miR-21 on cell proliferation was further analysed at 72 h after IR (Figure 3). Downregulation of miR-21 expression was found to reduce cell proliferation, as demonstrated by the decreased proliferation index of cells transfected with anti-miR-21 compared with anti-miR-NC (% versus 100%, ). Importantly, a more pronounced growth inhibition of A549 cells was found when miR-21 was knocked down in combination with IR. This inhibition of cell growth in the combined treatment (anti-miR-21 + IR) was found to be significantly higher compared with that in the sole IR treatment group (proliferation index: % versus %, , Figure 3). This indicates that knockdown of miR-21 sensitizes radioresistant NSCLC A549 cells to radiation.

3.4. Downregulation of miR-21 Enhanced Apoptosis of A549 Cells Induced by IR

We next explored the role of miR-21 in the apoptosis of NSCLC A549 cells induced by IR. Anti-miR-21 or anti-miR-NC was transfected into A549 cells and was exposed (or sham exposed) to 8 Gy of IR. As shown in Figure 4, the percentage of apoptosis cells in miR-21 knockdown group (anti-miR-21) was significantly higher than that of negative control group (anti-miRNA-NC) at the dose 8 Gy ( versus , ), indicating that miR-21 knockdown may enhance radiosensitivity of A549 cells by promoting apoptosis and thus confirm a role for miR-21 in the regulation of radiotherapy response of NSCLC.

3.5. Downregulation of miR-21 Inactivated PI3K/Akt Signaling Pathway Induced by IR

Because the PI3K/Akt signaling pathway is associated with apoptosis, we subsequently examined the potential effects of miR-21 on the activation of PI3K/Akt pathways by IR to explore the potential molecular mechanisms. The activation of PI3K/Akt signaling pathways was measured by Akt phosphorylation on Ser473. By Western blot, we found that the endogenous level of phospho-Akt expression (Ser473) in anti-miR-21-transfected A549 cells was downregulated compared to that in anti-miR-NC-transfected A549 cells after IR (Figure 5). Interestingly, phospho-Akt (Ser473) expression was significantly increased in the case of being treated with IGF-1, a PI3K activator, in anti-miR-NC-transfected A549 cells and even in anti-miR-21-transfected A549 cells after IR (Figure 5). This suggested that activation of PI3K/Akt signaling pathway by IR in A549 cells was suppressed by knockdown of miR-21, and the suppression was reversed by PI3K activator IGF-1.

3.6. miR-21 Knockdown Caused Promotion on Apoptosis Induced by IR Was Mediated by PI3K/Akt Signaling Pathway

To further confirm the molecular mechanisms of radiosensitization by miR-21 knockdown in NSCLC A549 cells, we next treated the cells with or without PI3K activator IGF-1 and then examined the effects of miR-21 downregulation on cell apoptosis induced by IR. As shown in Figure 6, without IGF-1 treatment, the cell apoptosis induced by IR was significantly increased in anti-miR-21-transfected A549 cells (%) compared with that in anti-miR-NC-transfected A549 cells (%, ). However, after activation of PI3K/Akt signaling pathway, the cell apoptosis induced by IR was inhibited in either anti-miR-21-transfected or anti-miR-NC-transfected A549 cells. The percentage of cell apoptosis was not significantly different between these two groups (% versus %, ). These data showed that, in the condition of PI3K/Akt activation, knockdown of miR-21 did not promote the apoptosis of A549 cells induced by IR, suggesting that PI3K/Akt signaling pathway was the downstream target of miR-21 and the promotive effects of miR-21 knockdown on apoptosis induced by IR were mediated by PI3K/Akt signaling pathway.

4. Discussion

It is well known that the acquisition of resistance to radiotherapy, which greatly increases patient morbidity and mortality, is a significant problem in the treatment of NSCLC. Effective treatment which can sensitize the radioresistant NSCLC to radiotherapy is always being sought. Recently, some miRNAs were found to be related to radioresistance. Among them, miR-21 is reported to play a role in radioresistance of cancer, including glioblastoma [26, 27], breast cancer [28], and rectal cancer [29]. But up to now, few researches have studied the correlations between miR-21 expression and radiotherapy sensitivity of NSCLC. Liu et al. reported that miR-21 expression promotes radioresistance in NSCLC, but the related molecular mechanisms were not revealed [30]. The roles of miR-21 in the radiotherapy response of NSCLC are not fully understood and remain to be elucidated. Thus, in the current study, we investigated whether miR-21 could affect the radiosensitivity of NSCLC A549 cells and found that downregulation of miR-21 significantly enhanced the sensitivity of A549 cells to radiotherapy through inhibition of PI3K/Akt signaling pathway.

Our data showed that, following the transfection of anti-miR-21 into A549 cells, the inhibition of survival fraction caused by various doses of IR was enhanced compared with radiotherapy alone. This result suggests that miR-21 is closely associated with the therapeutic efficiency of IR on radioresistant A549 cells and downregulation of miR-21 may sensitize A549 cells to IR.

It is reported that miR-21 could stimulate growth in NSCLC [30, 31]. Accordingly, we also found that the proliferation of A549 cells was inhibited after miR-21 knockdown. Moreover, the inhibition of cell proliferation induced by combination of miR-21 knockdown and IR was more pronounced compared with either miR-21 knockdown or IR treatment, indicating that miR-21 knockdown plays a crucial role in the combined inhibition of cell proliferation and silencing miR-21 may increase the sensitivity of A549 cells to IR.

Cell apoptosis induced by IR is one of the most important effects of tumor radiotherapy. Furthermore, miR-21 is reported to be an antiapoptotic factor in lung cancer [32, 33]. So, we hypothesized that it is possible that miR-21 could affect the apoptosis of NSCLC induced by IR. Our current results demonstrated that miR-21 knockdown promoted apoptosis of A549 cells induced by IR, indicating that the expression of miR-21 could affect radiosensitivity of NSCLC cells, which might be associated with inhibition of apoptosis. This is also in agreement with the previous report [30].

To explore the potential molecular mechanisms of radiosensitization by miR-21 knockdown in NSCLC A549 cells, we focused on analysis of PI3K/Akt signaling pathway because the influence of PI3K/Akt signaling pathway on IR-induced apoptotic propensity is well documented [34, 35]. We examined whether downregulation of miR-21 could affect Akt phosphorylation at Ser473 and/or its total expression and found that miR-21 knockdown suppressed the activation of PI3K/Akt signaling pathway by IR in A549 cells. In addition, the apoptosis induced by IR was enhanced in A549 cells after miR-21 knockdown. This data indicates that the stimulative effects of miR-21 knockdown on A549 cell apoptosis induced by IR are related to the inactivation of PI3K/Akt signaling pathway. Furthermore, with the treatment of PI3K activator IGF-1, we found that the apoptosis of A549 cells induced by IR was not promoted even if miR-21 was downregulated. Our results suggest that the promotive effects of miR-21 knockdown on A549 cell apoptosis induced by IR depend on the inactivation of PI3K/Akt signaling pathway. In the current study, how miR-21 interplays with PI3K/Akt signaling pathway under our experimental conditions is not clear. However, it is reported that molecules such as PTEN have been proposed to be involved in NSCLC cells’ radioresistance [36, 37] and miR-21 is related to PTEN with high possibility [30, 38]. In addition, since PTEN, PI3K, and Akt are closely related, it is one of the possible mechanisms that PTEN may play a role in PI3K/Akt signaling pathway mediated radiosensitization of A549 cells by miR-21 knockdown but this still needs further comfirmation in future studies.

In summary, the present study found that downregulation of miRNA-21 sensitized radioresistant NSCLC A549 cells to IR by inhibiting cell proliferation and enhancing apoptosis through inhibition of PI3K/Akt signaling pathway. This information may be useful to develop new treatments for the clinical therapy of NSCLC patients. Further analysis on targets of miR-21 is still of considerable interest, as they may reveal novel radiotherapy sensitization strategies for radioresistant NSCLC.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Yongfu Ma and Hui Xia contributed equally to this work.


  1. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA: Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008. View at: Publisher Site | Google Scholar
  2. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at: Publisher Site | Google Scholar
  3. P. Fidias and S. Novello, “Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 28, no. 34, pp. 5116–5123, 2010. View at: Publisher Site | Google Scholar
  4. A. D. Fuld, K. H. Dragnev, and J. R. Rigas, “Pemetrexed in advanced non-small-cell lung cancer,” Expert Opinion on Pharmacotherapy, vol. 11, no. 8, pp. 1387–1402, 2010. View at: Publisher Site | Google Scholar
  5. A. W. Whitehurst, B. O. Bodemann, J. Cardenas et al., “Synthetic lethal screen identification of chemosensitizer loci in cancer cells,” Nature, vol. 446, no. 7137, pp. 815–819, 2007. View at: Publisher Site | Google Scholar
  6. C. le Péchoux, “Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data,” Oncologist, vol. 16, no. 5, pp. 672–681, 2011. View at: Publisher Site | Google Scholar
  7. R. Danesi, G. Pasqualetti, E. Giovannetti et al., “Pharmacogenomics in non-small-cell lung cancer chemotherapy,” Advanced Drug Delivery Reviews, vol. 61, no. 5, pp. 408–417, 2009. View at: Publisher Site | Google Scholar
  8. F. Rödel, J. Hoffmann, L. Distel et al., “Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer,” Cancer Research, vol. 65, no. 11, pp. 4881–4887, 2005. View at: Publisher Site | Google Scholar
  9. S. Lee, M. J. Lim, M. H. Kim et al., “An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses,” Free Radical Biology & Medicine, vol. 53, pp. 807–816, 2012. View at: Google Scholar
  10. M. Provencio, A. Sánchez, P. Garrido, and F. Valcárce, “New molecular targeted therapies integrated with radiation therapy in lung cancer,” Clinical Lung Cancer, vol. 11, no. 2, pp. 91–97, 2010. View at: Publisher Site | Google Scholar
  11. R. C. Lee, R. L. Feinbaum, and V. Ambros, “The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14,” Cell, vol. 75, no. 5, pp. 843–854, 1993. View at: Publisher Site | Google Scholar
  12. M. V. Iorio and C. M. Croce, “MicroRNAs in cancer: small molecules with a huge impact,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5848–5856, 2009. View at: Publisher Site | Google Scholar
  13. N. M. A. White, E. Fatoohi, M. Metias, K. Jung, C. Stephan, and G. M. Yousef, “Metastamirs: a stepping stone towards improved cancer management,” Nature Reviews Clinical Oncology, vol. 8, no. 2, pp. 75–84, 2011. View at: Publisher Site | Google Scholar
  14. T. A. Farazi, J. I. Spitzer, P. Morozov, and T. Tuschl, “MiRNAs in human cancer,” Journal of Pathology, vol. 223, no. 2, pp. 102–115, 2011. View at: Publisher Site | Google Scholar
  15. C. M. Croce, “Causes and consequences of microRNA dysregulation in cancer,” Nature Reviews Genetics, vol. 10, no. 10, pp. 704–714, 2009. View at: Publisher Site | Google Scholar
  16. C. Ortholan, M.-P. Puissegur, M. Ilie, P. Barbry, B. Mari, and P. Hofman, “MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets,” Current Medicinal Chemistry, vol. 16, no. 9, pp. 1047–1061, 2009. View at: Publisher Site | Google Scholar
  17. J.-S. Oh, J.-J. Kim, J.-Y. Byun, and I.-A. Kim, “Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-ras,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 1, pp. 5–8, 2010. View at: Publisher Site | Google Scholar
  18. H. Salim, N. S. Akbar, D. Zong et al., “miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence,” British Journal of Cancer, vol. 107, pp. 1361–1373, 2012. View at: Google Scholar
  19. D. Yan, W. L. Ng, X. Zhang et al., “Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation,” PLoS ONE, vol. 5, no. 7, article e11397, 2010. View at: Publisher Site | Google Scholar
  20. A. Markou, I. Sourvinou, P. A. Vorkas, G. M. Yousef, and E. Lianidou, “Clinical evaluation of microRNA expression profiling in non small cell lung cancer,” Lung Cancer, vol. 81, pp. 388–396, 2013. View at: Google Scholar
  21. S. Li, Z. Liang, L. Xu, and F. Zou, “MicroRNA-21: a ubiquitously expressed pro-survival factor in cancer and other diseases,” Molecular and Cellular Biochemistry, vol. 360, no. 1-2, pp. 147–158, 2012. View at: Publisher Site | Google Scholar
  22. M. Yang, H. Shen, C. Qiu et al., “High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer,” European Journal of Cancer, vol. 49, pp. 604–615, 2013. View at: Google Scholar
  23. X.-C. Wang, L.-Q. Du, L.-L. Tian et al., “Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer,” Lung Cancer, vol. 72, no. 1, pp. 92–99, 2011. View at: Publisher Site | Google Scholar
  24. K. Lao, N. L. Xu, V. Yeung, C. Chen, K. J. Livak, and N. A. Straus, “Multiplexing RT-PCR for the detection of multiple miRNA species in small samples,” Biochemical and Biophysical Research Communications, vol. 343, no. 1, pp. 85–89, 2006. View at: Publisher Site | Google Scholar
  25. C. Chen, D. A. Ridzon, A. J. Broomer et al., “Real-time quantification of microRNAs by stem-loop RT-PCR,” Nucleic Acids Research, vol. 33, no. 20, article e179, 2005. View at: Publisher Site | Google Scholar
  26. A. Griveau, J. Bejaud, S. Anthiya, S. Avril, D. Autret, and E. Garcion, “Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death,” International Journal of Pharmaceutics, vol. 454, pp. 765–774, 2013. View at: Google Scholar
  27. Y. Li, S. Zhao, Y. Zhen et al., “A miR-21 inhibitor enhances apoptosis and reduces G2-M accumulation induced by ionizing radiation in human glioblastoma U251 cells,” Brain Tumor Pathology, vol. 28, no. 3, pp. 209–214, 2011. View at: Publisher Site | Google Scholar
  28. N. Anastasov, I. Hofig, I. G. Vasconcellos et al., “Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells,” Radiation Oncology, vol. 7, article 206, 2012. View at: Google Scholar
  29. U. Drebber, M. Lay, I. Wedemeyer et al., “Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy,” International Journal of Oncology, vol. 39, no. 2, pp. 409–415, 2011. View at: Publisher Site | Google Scholar
  30. Z. L. Liu, H. Wang, J. Liu, and Z. X. Wang, “MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN,” Molecular and Cellular Biochemistry, vol. 372, pp. 35–45, 2013. View at: Google Scholar
  31. J.-G. Zhang, J.-J. Wang, F. Zhao, Q. Liu, K. Jiang, and G.-H. Yang, “MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC),” Clinica Chimica Acta, vol. 411, no. 11-12, pp. 846–852, 2010. View at: Google Scholar
  32. M. E. Hatley, D. M. Patrick, M. R. Garcia et al., “Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21,” Cancer Cell, vol. 18, no. 3, pp. 282–293, 2010. View at: Publisher Site | Google Scholar
  33. M. Seike, A. Goto, T. Okano et al., “MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 29, pp. 12085–12090, 2009. View at: Publisher Site | Google Scholar
  34. W. Qiu, B. Leibowitz, L. Zhang, and J. Yu, “Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis,” Oncogene, vol. 29, no. 11, pp. 1622–1632, 2010. View at: Publisher Site | Google Scholar
  35. Y. Lei, H. X. Li, W. S. Jin et al., “The radiosensitizing effect of Paeonol on lung adenocarcinoma by augmentation of radiation-induced apoptosis and inhibition of the PI3K/Akt pathway,” International Journal of Radiation Biology, vol. 89, no. 12, pp. 1079–1086, 2013. View at: Google Scholar
  36. E. J. Kim, J. H. Jeong, S. Bae, S. Kang, C. H. Kim, and Y. B. Lim, “mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy,” Journal of Cellular Biochemistry, vol. 114, pp. 1248–1256, 2013. View at: Google Scholar
  37. I. L. Jung, H. J. Kang, K. C. Kim, and I. G. Kim, “PTEN/pAkt/p53 signaling pathway correlates with the radioresponse of non-small cell lung cancer,” International Journal of Molecular Medicine, vol. 25, no. 4, pp. 517–523, 2010. View at: Publisher Site | Google Scholar
  38. S. Roy, Y. Yu, S. B. Padhye, F. H. Sarkar, and A. P. Majumdar, “Difluorinated-curcumin, (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21,” PLoS One, vol. 8, article e68543, 2013. View at: Google Scholar

Copyright © 2014 Yongfu Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.